The Feasibility of Engage Therapy With Video Support for Homebound Older Adults
A Pilot Study of Delivering 'Engage' Psychotherapy Via Telemedicine Through the Tablet-based 'Prism' System to Homebound Older Adults With Depression
2 other identifiers
interventional
8
1 country
1
Brief Summary
The primary aim in this pilot project is to test the feasibility, acceptability and impact (decreased depressive symptoms) of a brief behavioral treatment for depression (Engage) combined with video social support (PRISM 2.0) among socially isolated/lonely case management clients who endorse depressive symptoms. Eligible participants will be offered the combination of Engage and Prism 2.0, called Engage-Prism. The investigators hypothesize that the intervention (Engage Therapy With Video Support) will be accepted by participants, improve depressive symptom, and be feasible to complete.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable depression
Started May 2022
Shorter than P25 for not_applicable depression
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 20, 2022
CompletedFirst Posted
Study publicly available on registry
April 26, 2022
CompletedStudy Start
First participant enrolled
May 12, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2022
CompletedResults Posted
Study results publicly available
June 28, 2023
CompletedJune 28, 2023
June 1, 2023
5 months
April 20, 2022
June 5, 2023
June 5, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Acceptability: Client Satisfaction Questionnaire (CSQ)
The CSQ is a 3 - item questionnaire assessing client satisfaction with the treatment provided partway through the treatment (6 weeks). Scores range from 3 (least satisfied) to 12 (most satisfied).
6 weeks (part-way through treatment)
Acceptability: Client Satisfaction Questionnaire (CSQ)
The CSQ is a 3 - item questionnaire assessing client satisfaction with the treatment provided assessed at 3 weeks post treatment (at 12 weeks) Scores range from 3 (least satisfied) to 12 (most satisfied).
12 weeks (post treatment)
Feasibility: Client Enrollment
Feasibility will be measured as the number of clients who are referred to the program, meet eligibility and accept the intervention (versus refuse).
Baseline
Secondary Outcomes (2)
Hamilton Depression Rating Scale
Baseline, 9 weeks (end of treatment)
Hamilton Depression Rating Scale
Baseline, 12 weeks (post treatment)
Study Arms (1)
Engage Prism 2.0
OTHEREngage Prism is a 9-week program that integrates Engage- a form of behavioral talk therapy treating depression, and guided use of Prism technology- a software that aims to improve social support and interaction of older adults.
Interventions
Brief Behavioral Treatment for Depression (Engage) combined with tablet-based social support system (Prism 2.0)
Eligibility Criteria
You may qualify if:
- Age at least 60 years
- English speaking
- Currently enrolled in case management at in 2 included agencies
- Major depression on the SCID
- item Hamilton Depression Rating Scale (HAM-D) ≥ 19
You may not qualify if:
- Psychotic depression by SCID-V, i.e. presence of delusions
- High suicide risk, i.e. intent or plan to attempt suicide in the near future
- Presence of any Axis I psychiatric disorder
- Presence of substance abuse other than unipolar major depression
- History of psychiatric disorders, hypomania, are excluded
- Acute or severe medical illness, i.e. delirium, metastatic cancer, decompensated cardiac, liver, or kidney failure, major surgery, stroke, or myocardial infarction during the three months prior to entry; or drugs often causing depression, e.g. steroids, reserpine, alpha- methyl-dopa, tamoxiphen, vincristine
- Current involvement in psychotherapy
- Cognitive impairment (i.e. telephone administered MoCA \< 11)
- Currently dwelling in non-community dwelling (e.g. prison, nursing home)
- Hearing that would not allow participants to complete sessions with the RA/therapist
- Vision impairment that would not allow the participant to use the study provided tablet
- Inability to speak English
- Aphasia interfering with communication
- Literacy -assessed by reading a paragraph designed for those at 6th grade reading level
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Weill Cornell Medicine
New York, New York, 10065, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Jo Anne Sirey
- Organization
- Weill Cornell Medical College
Study Officials
- PRINCIPAL INVESTIGATOR
Natalie C Benda, PhD
Weill Medical College of Cornell University
Publication Agreements
- PI is Sponsor Employee
- Yes
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 20, 2022
First Posted
April 26, 2022
Study Start
May 12, 2022
Primary Completion
September 30, 2022
Study Completion
September 30, 2022
Last Updated
June 28, 2023
Results First Posted
June 28, 2023
Record last verified: 2023-06
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF
- Time Frame
- After we publish the main results, we will make de-identified data available to other researchers under a data sharing agreement overseen by Weill Cornell Alacrity Center's executive committee.
- Access Criteria
- Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. All researchers requesting data solely for research purpose; secure the data; return or destroy it once analyses are completed; do not share it with other researchers.
Individual participant data that underlie the results in publications after de-identification, as well as study protocol, treatment manuals, statistical analysis plan and informed consent.